Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab + Atezolizumab + Polatuzumab Vedotin in R/R FL and DLBCL
NCT02729896Phase 2Completed
- Sponsor
- Roche
- Start
- Nov 2016
- Primary completion
- Sep 2018
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 3
01
Overview
Phase 2, open-label trial of polatuzumab vedotin in follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) (3 arms), sponsored by Roche. Primary endpoint: Percentage of Participants With Complete Response at End of Induction by PET-CT. Started Nov 2016; status: completed.
02
Drugs
polatuzumab vedotin
03
Conditions
follicular lymphoma (FL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02729896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02729896.